Related Experiment Video
Updated: Jun 3, 2026
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Lenalidomide - current understanding of mechanistic properties
1Department of Internal Medicine, Wayne State University/ Detroit Medical Center, MI 48201, USA. ntageja@med.wayne.edu
Anti-Cancer Agents in Medicinal Chemistry
|March 24, 2011
Summary
Lenalidomide, an immunomodulatory drug, shows promise for multiple myeloma treatment. Its exact anti-cancer mechanisms, whether direct cell death or immune system modulation, require further research for optimal therapeutic strategies.
Area of Science:
- Hematology
- Pharmacology
- Oncology
Background:
- Multiple myeloma (MM) treatment is evolving with better understanding of its pathophysiology.
- Thalidomide's reintroduction as an anti-neoplastic agent revolutionized MM therapy but had significant side effects.
- Immunomodulatory drugs (IMiDs) were developed as analogs of thalidomide to improve efficacy and tolerability.
Purpose of the Study:
- To elucidate the mechanistic properties of lenalidomide, a second-generation IMiD.
- To clarify the dual mechanisms of action for lenalidomide in cancer cell death.
- To provide insights for developing rational combination strategies in hematological malignancies.
Main Methods:
- Review of preclinical and clinical studies on lenalidomide.
- Analysis of lenalidomide's structural modifications from thalidomide.
- Examination of lenalidomide's immunomodulatory, antiangiogenic, and apoptotic properties.
Main Results:
- Lenalidomide possesses immunomodulatory, antiangiogenic, and direct apoptotic properties.
- Lenalidomide induces cancer cell death through direct interference or modulation of signaling pathways.
- The precise mechanisms and their contributions to clinical activity in MM remain unclear.
Conclusions:
- Understanding lenalidomide's complex mechanisms is crucial for optimizing its use in multiple myeloma.
- Further research is needed to differentiate the roles of direct tumoricidal activity versus immunomodulation.
- Elucidating these mechanisms will guide the development of effective combination therapies for hematological malignancies.
Related Concept Videos
01:21Pharmacodynamics: Overview and Principles
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or within...
01:24Principles of Drug Action
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
01:16Protein-Drug Binding: Mechanism and Kinetics
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...